RxDoctor Payments DataLook up a doctor →

Bradley Meek, MD

Internal Medicine · Baton Rouge, LANPI 1659379477

Payments from drug & device makers

$20,016in general payments, 2019–2025

Across 1,257 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Merck$2K
  • Lilly USA, LLC$2K
  • GSK$1K
  • AstraZeneca$994
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$1,3657%
  • Travel & lodging$250%
  • Food & beverage$18,59493%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)181$2,171
Novo Nordisk130$1,953
Merck34$1,821
Lilly USA, LLC109$1,540
GSK79$1,159
AstraZeneca45$994
Pfizer72$877
Boehringer Ingelheim55$734
Amgen56$709
Teva Pharmaceuticals USA, Inc.44$568
Johnson & Johnson44$551
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC36$535
Astellas Pharma US Inc31$533
Sanofi-aventis U.S. LLC35$492
Novartis26$379
Bayer18$373
Takeda Pharmaceuticals U.S.A., Inc.23$355
Abbott15$295
Antares Pharma, Inc.14$282
Amarin Pharma, Inc.20$273
Lundbeck LLC10$251
Otsuka America Pharmaceutical, Inc.18$238
Vanda Pharmaceuticals Inc.11$210
Sunovion Pharmaceuticals Inc.12$195
Esperion Therapeutics, Inc.7$188
Dexcom, Inc.4$179
Sumitomo Pharma America, Inc.10$152
Phathom Pharmaceuticals, Inc.11$147
Acadia Pharmaceuticals Inc8$137
Avanir Pharmaceuticals, Inc.7$119
Eisai Inc.4$110
Nevro Corp.1$98
E.r. Squibb & Sons, L.L.C.7$93
Gilead5$87
Supernus Pharmaceuticals, Inc.6$78
Jazz Pharmaceuticals Inc.3$68
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$65
Ironwood Pharmaceuticals, Inc4$62
Kowa Pharmaceuticals America, Inc.4$62
Biogen3$59
Almatica Pharma LLC3$58
Ardelyx, Inc.3$52
Exact Sciences3$50
Xeris Pharmaceuticals, Inc.2$47
Tolmar, Inc.3$46
Vivus LLC4$46
Biohaven Pharmaceutical Holding Company Ltd.3$40
Corium, LLC4$38
Corcept Therapeutics2$32
Amneal Pharmaceuticals LLC2$30
Currax Pharmaceuticals LLC2$29
Rhythm Pharmaceuticals, Inc.1$27
Shield Therapeutics Inc2$27
IBSA Pharma Inc.1$23
Collegium Pharmaceutical, Inc.1$21
Nestle Healthcare Nutrition Inc.1$21
Genentech USA, Inc.1$21
Sanofi1$20
Neurocrine Biosciences, Inc.1$19
Sanofi Pasteur Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,016 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$173,327
Medicare patients
378
Services billed
2,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide333$379,818
OzempicSemaglutide219$277,499
JardianceEmpagliflozin186$162,855
TrulicityDulaglutide57$68,870
LinzessLinaclotide65$47,288
EliquisApixaban35$31,838
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$27,827
MyrbetriqMirabegron44$27,778
Repatha SureclickEvolocumab36$26,902
FarxigaDapagliflozin Propanediol31$23,379
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$11,789
TradjentaLinagliptin15$10,579
Tresiba Flextouch U-200Insulin Degludec12$10,400
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,865
Gabapentin255$3,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,540$448,688390 claims
Novo NordiskOzempic$1,953$277,499219 claims
Boehringer IngelheimJardiance, Tradjenta$734$173,434201 claims
AbbVieLinzess$2,171$47,28865 claims
PfizerEliquis$877$31,83835 claims
GSKTrelegy Ellipta$1,159$27,82740 claims
Astellas Pharma US IncMyrbetriq$533$27,77844 claims
AstraZenecaFarxiga$994$23,37931 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$1,843240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →